Bispecific BCMA/CD19 targeted CAR-T cell therapy forces sustained disappearance of symptoms and anti-acetylcholine receptor antibodies in refractory myasthenia gravis: a case reportYong Zhang, Guiyun Cui, Jiang Cao et al.|Journal of Neurology|2024Cited by 28
Anti-BCMA/CD19 CAR T cell therapy in patients with refractory generalized myasthenia gravis: a single-arm, phase 1 trialYong Zhang, Ming Shi, Dan Liu et al.|EClinicalMedicine|2025Cited by 12